Evidence map›Paper›PMID 38531630›Full record

ArticleFEBS open bio2024

Ezetimibe inhibits the migration and invasion of triple-negative breast cancer cells by targeting TGFβ2 and EMT.

Lingkai Kong, Qinyu He, Ding Ma, Weiwei Shi, Qilei Xin, Chunping Jiang, Junhua Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. [Erianin inhibits proliferation and migration of breast cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lingkai KongJinan Microecological Biomedicine Shandong Laboratory, China.
Qinyu HeState Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, China.
Ding MaState Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, China.
Weiwei ShiState Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, China.
Qilei XinJinan Microecological Biomedicine Shandong Laboratory, China.
Chunping JiangJinan Microecological Biomedicine Shandong Laboratory, China.
Junhua WuJinan Microecological Biomedicine Shandong Laboratory, China.ORCID 0000-0003-4753-2648
China Pharmaceutical University · CNCluster in Biomedicine · IT

Funding

National Natural Science Foundation of China 81972888National Natural Science Foundation of China 82272819Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine 2020YLXK007Primary Research & Development Plan of Jiangsu Province BE2022840Research Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-202204AResearch Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-202219BResearch Project of Jinan Microecological Biomedicine Shandong Laboratory JNL-2023017DShandong Provincial Laboratory Project SYS202202
6 · The paper itself

Abstract

The important role of cholesterol in tumor metastasis has been widely studied in recent years. Ezetimibe is currently the only selective cholesterol uptake inhibitor on the market. Here, we explored the effect of ezetimibe on breast cancer metastasis by studying its impact on breast cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT). Differential gene expression analysis and validation were also carried out to compare ezetimibe-treated and untreated breast cancer cells. Finally, breast cancer cells overexpressing TGFβ2 were constructed, and the effect of TGFβ2 on the migration and invasion of ezetimibe-treated breast cancer cells was examined. Our results show that ezetimibe treatment of breast cancer cells inhibited cell migration, invasion, and EMT, and it significantly suppressed the expression of TGFβ2. Overexpression of TGFβ2 reversed the inhibitory effect of ezetimibe on the migration and invasion of breast cancer cells. Taken together, our results suggest that ezetimibe might be a potential candidate for the treatment of breast cancer metastasis.

Indexed as

Cell MovementEpithelial-Mesenchymal TransitionEzetimibeTransforming Growth Factor beta2Triple Negative Breast NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessEzetimibeTGFB2 protein, humanTransforming Growth Factor beta2breast cancercholesterolezetimibemetastasisTGFβ2

Identifiers

PMID38531630
PMCPMC11073500
OpenAlexW4394761633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.